Tesamorelin: what experts said, Q2 2026

Tesamorelin is the only GHRH analogue with an FDA approval, and it is approved for exactly one indication: reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy^[1]. It has no marketing authorisation in the EU, EEA or UK. That narrow regulatory footprint has not stopped the molecule from becoming one of the most discussed peptides in the longevity and body-composition space. Here is what credentialed experts have said about tesamorelin over the last 12 weeks, and what the published literature actually supports.

What the trial data shows

A 2026 meta-analysis by Badran and colleagues pooled five randomised controlled trials of tesamorelin versus placebo in adults with HIV-associated lipodystrophy^[2]. The headline numbers: visceral adipose tissue fell by a mean of 27.7 cm squared (95% CI: 17.1 to 38.4, p < 0.001), trunk fat dropped by 1.18 kg, and lean body mass rose by 1.42 kg. Hepatic fat decreased by 4.28 percentage points. Subcutaneous fat and BMI did not change meaningfully. The adverse-event profile was consistent with the FDA label: arthralgia, myalgia, injection-site reactions, and peripheral oedema, with no serious complications in the pooled dataset.

Those numbers matter because they set the boundary of what tesamorelin has actually been shown to do in controlled trials. Every result above is in the HIV-lipodystrophy population, on the labelled dose, against placebo. The meta-analysis did not study healthy adults using tesamorelin for general body composition, anti-ageing, or cognitive purposes.

The FDA label for Egrifta WR (the current US formulation) specifies 1.28 mg subcutaneously once daily, with contraindications for active malignancy, disrupted pituitary function, and pregnancy^[1]. The most common adverse reactions reported at greater than 5% incidence include arthralgia, injection-site erythema, pain in extremity, peripheral oedema, and myalgia. The label also warns about elevated IGF-1 requiring periodic monitoring and the possibility of glucose intolerance, which is consistent with the growth-hormone-axis mechanism.

What Topol said about the off-label drift

Eric Topol addressed tesamorelin directly in his July 2025 Ground Truths essay "The Peptide Craze," which surveyed 15 injectable peptides being used without approval or off-label^[3]. Topol called tesamorelin "an FDA approved drug for a narrow indication (patients with HIV lipodystrophy)" and noted it "is being prescribed for healthy individuals to reduce abdominal fat, improve muscle mass and cognitive health." He grouped it with CJC-1295 and ipamorelin as growth-hormone-related peptides that "carry the potential risk of cancer" by virtue of inducing broad cell growth.

There is no evidence from randomized trials in humans that any of these peptides provide the benefits that are advocated.

The quote above covers the full class, not tesamorelin alone. Topol's point is that the approved efficacy (visceral-fat reduction in HIV lipodystrophy) does not transfer to the off-label uses that drive most of the online conversation. For the approved indication, the trial evidence is real. For everything else, it is not there yet. That distinction is the load-bearing wall in any honest discussion of the molecule. See our tesamorelin page for the full regulatory and evidence picture.

Huberman's framing and its limits

Andrew Huberman, on a 2024 episode of the goop podcast, grouped tesamorelin with ipamorelin and MK-677 as "growth hormone secretagogues that people take before sleep to promote growth hormone release in sleep"^[4]. Huberman described tesamorelin as sitting in a "less mysterious" bucket than purely grey-market peptides because it is FDA-approved. That framing is accurate as far as it goes: tesamorelin does have an FDA approval, and its manufacturing and safety profile are better characterised than any research-chemical peptide.

Where the framing falls short is in the gap between the approved indication and the sleep and body-composition uses Huberman was describing. The FDA approval covers HIV-associated lipodystrophy, not growth-hormone optimisation in healthy adults. Huberman did not draw that distinction on air, which leaves the listener with a "less mysterious" impression that extends further than the regulatory record supports.

It is worth registering that Huberman's commercial relationships include the Momentous supplement line and a long track record of supplement-company sponsorships, which does not invalidate his points but does place them in a promotional ecosystem that benefits from enthusiasm about peptides broadly. The tesamorelin claim specifically ("FDA approved") is factually correct; the implied extension to sleep and body-composition uses in healthy people is where the evidence runs out.

What this is not

A recommendation for or against tesamorelin. An endorsement of off-label use. Or a dismissal of the molecule's real, trial-backed efficacy in its approved indication. Tesamorelin reduced visceral fat in HIV lipodystrophy in every trial that tested it, and the 2026 meta-analysis confirms the pooled effect is statistically and clinically meaningful. The honest summary is that we have strong evidence for one narrow use and essentially no controlled evidence for the uses that generate most of the public interest.

We also do not know the long-term cancer-incidence profile in non-HIV populations. Topol's cancer-risk flag is theoretical, rooted in the fact that growth-hormone and IGF-1 elevation promotes cell proliferation broadly, not just in the tissues you want. The FDA label lists active malignancy as a contraindication, and the EMA's 2012 concerns about insufficient long-term safety data (specifically around IGF-1 and cardiovascular endpoints) contributed to the European marketing-authorisation withdrawal. No sponsor has re-applied since.

Where this sits on the site

Our tesamorelin page covers the full mechanism, the FDA label, the EU withdrawal, and the practical access picture by country. The tesamorelin regulation section has the jurisdiction-specific detail. This digest captures what named experts said this quarter and where the evidence boundary sits. If you are considering tesamorelin for any purpose, that decision belongs with a prescribing clinician who knows your history.